A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments

Prior to his foray into the C-suite of a lean biotech, Nadim Ahmed spent his career in clinical development, medical affairs, and business management. Now, having taken the helm as President and CEO at Cullinan Oncology, his team is leveraging speed and innovation to bring new oncologic treatments to patients. As a small, clinical-stage company, Cullinan must prioritize resources and be nimble as they identify only the most effective candidates to bring to the clinic. Though easier said than done, by using their modality-agnostic discovery process, the Cullinan team has built a diverse, efficient approach that is empowering them on their path to becoming a fully integrated commercial biotech company.

In an episode of The Business of Biotech podcast, Ahmed explained that while he didn’t set out to become a leader in biotech, he recognized opportunities at Cullinan that he couldn’t pass up. Download the full article to learn more about how Cullinan is designing an exciting model that emphasizes the importance of culture, strategy, and execution.